MRes: Novel kinase inhibitors as anti tumour agents
The project will develop novel inhibitors of mTOR kinase and other related cancer chemotherapy targets, extending our recent published work on bridged bicyclic morpholines (Chemical Communications 2013, 49, 8931). Biological evaluation of these compounds using a combination of cell-free and cell-based assays will be employed to determine the extent of mTOR pathway modulation in normal and cancer cells. The work will be focused on synthetic organic chemistry. The successful candidate will have a degree in chemistry or pharmacy, excellent practical skills and a strong interest in synthetic and medicinal chemistry.
This project is only for one year.